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Abstract: BASIK2 is a prospective, double-blind, randomized placebo-controlled trial investigating
the effect of vitamin K2 (menaquinone-7;MK7) on imaging measurements of calcification in the
bicuspid aortic valve (BAV) and calcific aortic valve stenosis (CAVS). BAV is associated with
early development of CAVS. Pathophysiologic mechanisms are incompletely defined, and the only
treatment available is valve replacement upon progression to severe symptomatic stenosis. Matrix
Gla protein (MGP) inactivity is suggested to be involved in progression. Being a vitamin K dependent
protein, supplementation with MK7 is a pharmacological option for activating MGP and intervening
in the progression of CAVS. Forty-four subjects with BAV and mild–moderate CAVS will be included
in the study, and baseline 18F-sodiumfluoride (18F-NaF) positron emission tomography (PET)/
magnetic resonance (MR) and computed tomography (CT) assessments will be performed. Thereafter,
subjects will be randomized (1:1) to MK7 (360 mcg/day) or placebo. During an 18-month follow-up
period, subjects will visit the hospital every 6 months, undergoing a second 18F-NaF PET/MR after
6 months and CT after 6 and 18 months. The primary endpoint is the change in PET/MR 18F-NaF
uptake (6 months minus baseline) compared to this delta change in the placebo arm. The main
secondary endpoints are changes in calcium score (CT), progression of the left ventricularremodeling
response and CAVS severity (echocardiography). We will also examine the association between early
calcification activity (PET) and later changes in calcium score (CT).
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1. Introduction
A bicuspid aortic valve (BAV), an aortic valve consisting of two leaflets instead of three, is a
common congenital abnormality, occurring in 13.7 per 1000 people in the general population, with a
male predominance (3:1) [1,2]. BAV is associated with significant valvular and vascular morbidity and
early development of calcific aortic valve stenosis (CAVS) is common. In general, CAVS is characterized
by progressive narrowing of the aortic valve and is a known contributor to cardiovascular morbidity
and mortality, set to become a major healthcare burden. Clinical trials have not yet presented us with a
pharmacological treatment option to allow intervention in the progression of CAVS (Tables 1 and A1).
Therefore, today, the only treatment option for severe CAVS is valve replacement [3]. In patients with
BAV, valve replacement is usually indicated between the fourth and sixth decade, which is earlier than
in tricuspid aortic valve (TAV) stenosis, in general [4]. This suggests that, in patients with BAV, CAVS
shows a more rapid rate of progression [5]. For both BAV and TAV there is an unmet clinical need to
delay disease progression.
Progressive narrowing of the aortic valve is initially caused by lipid infiltration, inflammation
and micro-calcification (the very early stages of calcification) and, upon progression, pro-osteogenic
and pro-calcific mechanisms dominate, ultimately leading to severe CAVS [6–9]. These calcific
regulatory pathways include Notch, receptor activator of nuclear factor kappa B(RANK)/receptor
activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG), Wnt/b-catenin and
bone morphogenetic proteins (BMPs) [8]. BMP-2 is a key protein of the valvular interstitial cell (VIC)
phenotype switching, and thus is highly involved in the progression of calcification. The binding of
BMP-2 to its receptor is inhibited by matrix Gla-protein (MGP). Moreover, MGP can directly interact
with hydroxyapatite (micro-calcification), inhibiting the growth of hydroxyapatite crystals in vascular
tissue [10] and stabilising calcifying protein particles (CPPs) in the circulation [11].
MGP is a vitamin K-dependent protein which needs to undergo carboxylation to become
biologically active [10]. In CAVS, the active carboxylated MGP is decreased, thereby inhibiting
the ability to inhibit progression of valvular calcification [12]. The beneficial effects of vitamin K in
inhibiting vascular calcification have been studied [13,14], but data on the potential effects on CAVS
are lacking. Menaquinone-7 (MK7; vitamin K2) has a long half-life (about 3 days [15]) and is reported
to have a significantly higher bioavailability and bioactivity in vivo compared to vitamin K1 [16].
BASIK2 is being conducted to investigate the effect of vitamin K2, more specifically MK7, on
valvular calcification in CAVS, as evaluated by 18F-sodiumfluoride (18F-NaF) positron emission
tomography (PET)/magnetic resonance (MR). PET is a molecular imaging technique that enables the
visualization of calcification activity in the valve. The PET tracer, 18F-NaF preferentially binds to areas
of developing microcalcification [17], predicting where larger macrocalcific deposits will ultimately
develop, and, as a consequence, predicting future aortic stenosis progression [18,19]. Integrated MR
imaging enables simultaneous evaluation of left ventricular function and structure [20], as well as the
visualization of valve morphology and function [21]. It is not hampered by calcification artifacts as seen
in computed tomography (CT). Therefore, PET/MR provides incremental information to the standard
methods (echocardiography and CT) used to measure aortic valve stenosis and calcification [22].
The principal objective of BASIK2 is to provide evidence to support the hypothesis that MK7
inhibits calcification activity in patients with BAV and CAVS. If successful, this would position this
simple, safe and naturally occurring agent as the first effective treatment for aortic stenosis and set the
foundations for larger phase 3 clinical outcome studies. In addition, the innovative use of sequential
18F-NaF PET may help to confirm this hypothesis 6 months after the initiation of therapy. If the change
in this parameter predicts the observed changes in CT aortic valve calcification (AVC) and valve
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hemodynamic at 18 months, then this novel trial design could be used more widely to rapidly and
efficiently test the efficacy of other potential therapies in phase 2 clinical trials.
2. Trial Design
The BASIK2 trial is an investigator-initiated, prospective, double blind, randomized,
placebo-controlled trial, studying the effects of vitamin K2 (menaquinone-7, MK7) or placebo on the
progression of calcification in CAVS using 18F-NaF PET/MR in patients with a bicuspid aortic valve
and calcific aortic valve stenosis. The study was approved by the institutional review board (Maastricht
Academic Hospital and Maastricht University, the Netherlands: NL54600.068.015/METC152045) and
conducted according to the principles of the Declaration of Helsinki. The BASIK2 trial is registered
in clinicaltrials.gov as NCT02917525. All subjects gave their written informed consent for inclusion
before they participated in the study.
In subjects meeting requirements for trial participation an 18F-NaF PET/MR and a non-contrast
CT will be performed at baseline after providing informed consent. Furthermore, echocardiography
and venipuncture will be performed. Thereafter, subjects will be randomized (1:1) to the intervention or
control group, receiving an oral dose of 360 micrograms (mcg) menaquinone-7 or placebo respectively
(NattoPharma ASA, Hovik, Norway). The total study duration is 18 months, in which subjects will
visit the outpatient clinic every six months. After six months, subjects will again undergo PET-MR, and
uptake of 18F-NaF will be quantified to assess the (difference in) active calcification of the aortic valve
and the potential effect of MK7 supplementation. Furthermore, subjects will undergo a (non-contrast)
CT after 6 and 18 months. Transthoracic echocardiography and venipuncture will be performed
every visit during the follow-up period. Additional clinical information (such as medical history,
cardiovascular risk factors, current medication, family history) will be obtained from the electronic
hospital charts and will be evaluated every visit (if relevant).
The study flowchart is illustrated in Figure 1. These investigations will enable the evaluation of
several effects of MK7 and (the natural course of) progression of CAVS in this population, in addition
to the pre-specified primary endpoint. The total study population will consist of 44 patients.
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Figure 1. Study flowchart.* Primary endpoint (change from baseline in tracer uptake in the aortic
valve by 18F-NaF PET/MR at 6 months). Abbrevations: 18F-NaF; 18F-sodiumfluoride, CT; computed
tomography, MR; magnetic resonance, PET; positron emission tomography.
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Table 1. Overview of randomized controlled trials, performed with various pharmacological interventions, to halt progression of calcification in aortic valve stenosis.
Intervention Trial
Year or
Clinicaltrials.gov
Number
No. of
Patients Main Inclusion Criteria Primary Endpoint Conclusion
Atorvastatin vs.
placebo
SALTIRE
(Scottish Aortic Stenosis
and Lipid Lowering Trial:
Impact on Regression) [23]
2005 155
Patients (>18 years) with aortic
valve stenosis (Vmax ≥ 2.5 m/s)
and aortic valve calcifications,
without indications for AVR
Calcium score and Vmax
progression in atorvastatin,
arm vs. placebo (using
echocardiography and cardiac
CT at baseline, 12 and
24 months)
Atorvastatin had no
effect on the rate of
change in Vmax or
valvular calcification
Atorvastatin vs.
placebo
TASS
(Tyrolean Aortic Stenosis
Study) [24]
2008 47
Patients (>18 years) with aortic
valve stenosis (mean gradient
≥15 mmHg, Vmax ≥ 2.0 m/s)
and aortic valve calcifications,
without indications for AVR
Calcium score and mean
pressure gradient progression
in atorvastatin arm vs. placebo
(using echocardiography and
cardiac CT at baseline, 12 and
24 months)
Atorvastatin did not
reduce progression of
CAVS based on mean
pressure gradient and
aortic valve calcification
Vitamin K1
Slower progress of aortic
valve calcification with
vitamin K supplementation.
Results from a prospective
interventional
proof-of-concept study [25]
2017 99
Patients with asymptomatic or
mildly symptomatic aortic
valve calcification (Vmax >
2.0 m/s), without indications
for aortic valve replacement
Difference in progression of
aortic valve calcification
between the vitamin K arm
and the placebo arm (using
cardiac CT at 1 year)
Vitamin K might
decelerate the
progression of aortic
valve calcification,
measured by cardiac CT
when compared
to placebo.
PCSK9 inhibitor
vs. placebo
PCSK9 inhibitors in the
progression of aortic
stenosis
NCT03051360 140
Patients (>18 years) with mild
to moderate aortic valve
stenosis
Calcium score progression in
the PCSK9 treated arm vs.
placebo arm (using cardiac CT
and NaF PET at 2 years)
Not available
Niacin vs. placebo
EAVaLL
(Early Aortic Valve
Lipoprotein(a)
lowering trial)
NCT02109614 238
Patients (51–84 years) with
presence of aortic sclerosis or
mild aortic stenosis (AVA >
1.5 cm2, mean gradient
25 mmHg) and high Lp(a)
(>50 mg/dL)
Calcium score progression in
the niacin arm compared to the
placebo arm (using cardiac CT
at 2 years)
Not available
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Table 1. Cont.
Intervention Trial
Year or
Clinicaltrials.gov
Number
No. of
Patients Main Inclusion Criteria Primary Endpoint Conclusion
Alendronic acid
vs. placebo;
Denosumab vs.
placebo
SALTIRE II and RANKL
inhibition in aortic stenosis
(Study investigating the
effect of drugs used to treat
osteoporosis on the
progression of calcific
aortic stenosis)
NCT02132026 150
Patients (>50 years) with aortic
valve stenosis based on
echocardiography (Vmax >
2.5 m/s and grade 2–4
calcification), without
indications for valve
replacement surgery
Change in aortic valve calcium
score (using CT at baseline,
6 months and 2 years)
Not available
Ataciguat vs.
placebo
A Study Evaluating the
Effects of Ataciguat
(HMR1766) on Aortic Valve
Calcification (CAVS)
NCT02481258 35
Patients (>50 years) with mild
to moderate aortic valve
stenosis/calcification (1.0 <
AVA < 2.0 cm2, calcium level >
300 AU and LVEF > 50%)
Change in aortic valve calcium
between the HMR1766 arm vs.
the placebo arm (using CT at 6
and 12 months)
Not available
Phytine
CALCIFICA
(Value of oral phytate in the
prevention of progression
of cardiovascular
calcifications)
NCT01000233 250
Patients (>18 years) with
calcium in the aortic valve
(characterized by Rosenhek
score grade 2/3 on
echocardiography)
Calcium in the aortic valve and
in the coronary arteries in the
phytine arm vs. the placebo
arm (using CT at 24 months)
Not available
AVA: aortic valve area, AVR: aortic valve replacement, AU: Agatston units, CMR: cardiac magnetic resonance, CT: computed tomography, Lp(a): lipoprotein(a), LVEF: left ventricular
ejection fraction, LVM: left ventricular mass, MGP: matrix Gla protein, PCSK9: proprotein convertase subtilisin/kexin type 9, NaF PET: sodium fluoride positron emission tomography,
RAS: renin–angiotensin system, Vmax: peak velocity.
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3. Inclusion and Exclusion Criteria
A detailed overview of inclusion and exclusion criteria is provided in Table 2. In short, all patients
(>18 years) being followed up at the outpatient clinics of the Maastricht University Medical Center+
(MUMC+) with a bicuspid aortic valve (BAV), mild to moderate aortic valve stenosis and calcification
confirmed on echocardiography will be screened for eligibility. The presence of BAV will be confirmed
using short-axis echocardiographic images and morphology will be determined during systole [26].
Patients who meet any of the exclusion criteria (including standard contra-indications for MR) and
those unable to provide written informed consent will not be included.
Table 2. Eligibility criteria.
Inclusion criteria
√
Age > 18 years
√
Presence of bicuspid aortic valve
√
Calcified mild to moderate aortic valve stenosis (mean gradient < 40 mmHg, maximum gradient
between 25–64 mmHg or Vmax between 2.5–4 m/s)
Exclusion criteria
- Absence of bicuspid aortic valve
- Absence of calcified aortic valve stenosis (mean gradient < 10 mmHg, Vmax < 2.5 m/s or AVA 3–4 cm2)
- Presence of severe aortic valve stenosis (mean gradient > 40 mmHg, maximum gradient > 64 mmHg or
AVA < 1.0 cm2)
- Aortic valve replacement or repair (scheduled)
- Accepted atrial fibrillation
- Use of vitamin K antagonists
- Malignant disease < 2 years (except non-melanoma skin cancer, or in situ carcinoma of the cervix)
- Life expectancy < 2 years
- Present pregnancy or wish for near future pregnancy
- Claustrophobia
- Metallic implant (neurostimulator, cochlear implant, vascular clip)
- Pacemaker or ICD
- Adipositas per magna
Vmax: peak jet velocity; AVA: aortic valve area; ICD: implantable cardiac defibrillator.
4. Study Objectives and Statistical Analyses Plan
4.1. Primary End Point and Sample Size Calculation
The central aim of the current trial is to assess whether supplementation with menaquinone-7 will
slow or even reverse aortic valve calcification activity. Therefore, the primary endpoint is the change
in 18F-NaF tracer uptake on 18F-NaF PET/MR (6 months minus baseline).
At the time that the current study was designed, literature reporting the specified treatment effect
in similar studies was sparse. Therefore, the sample size calculation was based on expected changes in
CT calcium scores at the secondary endpoint [22,27,28]. The mean annual calcification progression
on CT has been estimated to be 21.7%, with a standard deviation of 19.8% [23]. Considering these
premises, the variability of the calcification progression is estimated to be comparable to the standard
deviation mentioned above (19.8%). An absolute difference in calcification progression of 20% between
the groups is considered a significant effect. With a significance level alpha of 0.05, a power of 80%
and an estimated dropout of approximately 25%, 44 patients will be required to detect a difference
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between the treatment groups (~22 subjects each) [29]. This power calculation is conservative since
change in CT calcium score is considered less sensitive than changes in 18F-NaF uptake [18], and the
calculated number of individuals is expected to afford more power to demonstrate a treatment effect
for the primary endpoint (18F-NaF uptake). 18F-NaF tracer uptake was shown to be present in patients
with CAVS in regions overlying, adjacent to and remote from existing valvular calcification [30], and
a recent study provided the first preliminary evidence that 18F-NaF is a very sensitive marker of
progression of aortic valve disease [18]. The six month time window between baseline and follow up
measurement with molecular PET imaging is also rather conservative and was derived from earlier
studies investigating the effect of short-term statin therapy on vascular inflammation and calcification
on fluorodeoxyglucose (FDG) PET/CT, showing a significant reduction in tracer uptake after 3 months
of treatment [31,32].
Since it is known that progression of aortic valve stenosis is not a linear process, but rather
shows a trend towards an increasing progression rate in advanced disease [33], patients with less than
mild aortic valve stenosis and patients with severe calcified aortic valve stenosis at baseline will be
excluded. Patients with a bicuspid aortic valve have an increased risk for aortic valve replacement
from approximately the fourth decade in life [4], suggesting a more rapid rate of progression, possibly
due to altered hemodynamic circumstances [5].
4.2. Secondary Endpoints
Secondary objectives include the following: change from baseline in calcium score of the aortic
valve measured by CT after 6 and 18 months, the correlation between tracer uptake after 6 months and
calcium score by CT after 18 months, change from baseline in echocardiographic parameters depicting
the progression of CAVS, the response of left ventricular (LV) function to CAVS on echocardiography,
and the change from baseline in left ventricular function, left ventricular mass, aortic distensibility and
aortic flow on MR after 6 months. Furthermore, the LV response to aortic valve stenosis, as measured
by changes in resting cardiac troponin and NTproBNP will be investigated, as well as associations
between changes in biomarkers and progression of calcification after 6, 12 and 18 months.
Data from all included patients will be used for the analyses. In the case of exclusion of a
patient during the trial, data from the patient will be collected and included in the analyses up until
their exclusion.
4.3. Additional Analyses
The main outcome parameter (change in calcification activity between the MK7-treated arm
and placebo) will be presented as a continuous variable. The mean difference in calcification activity
between treatment arms will be expressed as the difference between 18F-NaF uptake during follow-up
and 18F-NaF uptake at baseline. The CT calcium score will be presented as a continuous variable, and
the calcification (score) progression will be expressed as the mean difference (calcium score (aortic
valve) during follow-up minus calcium score (aortic valve) at baseline) and will be presented as a
dichotomous variable (rapid progression and slow progression).
Data will be analyzed based on the intention-to-treat principle. Baseline and follow-up
categorical variables will be expressed as percentages and continuous variables as means ± standard
deviations. The independent t-test or Mann–Whitney U test will be used to test differences between
normally-distributed continuous variables and continuous variables not showing a normal distribution,
respectively. A paired t-test or Wilcoxon signed rank test will be applied when appropriate. Categorical
variables will be tested using the Fisher’s exact or Chi square test. A two-sided significance level of 5%
will be considered to be statistically significant.
Univariate analysis and multiple regression analysis will be used to investigate the existence of
significant predictor(s) for the outcome variable—calcification progression.
Nutrients 2018, 10, 386 8 of 16
5. Study Procedures
5.1. PET and MR Imaging
Combined PET/MR scans will be performed at inclusion and after 6 months of follow-up using a
full-integrated Tesla PET-MR scanner (Siemens Biograph MmrTM, Siemens Healthineers, Forchheim,
Germany). A dose of 185 MBq of NaF will be injected intravenously. After 30 min, (non-contrast) MR
scanning will be started. PET data acquisition will be started 60 min after intravenous administration
of the radiopharmacon. Dixon-based MR images will be used for attenuation correction.
Heart and large vessel anatomy will be determined using a T1-weighted black blood sequence
(transversal and oblique sagittal plane) turbo spin echo sequence, prospectively triggered (average
repetition time (TR)/echo time (TE): 740 ms/27 ms, resolution 1.3 × 1.3 × 8.0 mm). Cine-MR views
of the heart in the horizontal and vertical long axes, short axes and left ventricular outflow tract will
be acquired according to standard clinical protocols to obtain ventricular volume, mass and function,
and 3–5 slices of cross sectional cine images at the level of the aortic root will be acquired to obtain
valvular anatomy and function (all cine images: balanced fast field echo sequence, retrospectively
triggered. TR/TE/flip angle: 41.28 ms/1.51 ms/50◦, resolution 1.3× 1.3× 8.0 mm). Flow imaging will
be performed at the level of the aortic valve and the ascending aorta. Analyses of source images will be
performed using dedicated software (Syngo.viaTM, Siemens Healthineers, Forchheim, Germany). PET
signal quantification will be performed by delineating regions of interest (ROI) using both PET and
MR images. Moreover, (non-contrast) CT images will be used to localize regions of macrocalcification.
5.2. Computed Tomography (CT) Imaging
A breath-held, non-contrast, enhanced CT scan will be performed at inclusion and during
the visits at 6 and 18 months of follow-up to determine calcification of the aortic valve and the
thoracic aorta. These scans will be performed using a third generation, dual-source CT-scanner
(Somatom Definition Force, Siemens Healthineers, Forchheim, Germany). The scan protocol for
calcium scoring will be performed at a tube voltage of 120 kV, reference quality tube current of 80 mAs,
2 × 192 × 0.6 mm collimation, a gantry rotation time of 0.25 s and a pitch value of 3.2. Calcification
quantification (mass, volume and score) of the aortic valve and the thoracic aorta will be determined
using dedicated post-processing software (Syngo.via, Siemens Healthineers, Forchheim, Germany) [27].
Calcium localized from the sinotubular junction to the end of scan range, or up to the origin of the
brachiocephalic artery, is considered to be in the ascending aorta. Calcium present distal from the
origin of the left subclavian artery up to the diaphragm is considered to be localized in the descending
aorta. Quantification will be performed by two observers, both blinded to medical data. In the case of
ambiguity, consensus will be reached by discussion/in the presence of a third observer.
5.3. Echocardiography
Transthoracic echocardiographic examinations will be performed every 6 months. All parameters
(presented in Table 3) are part of the regular echocardiographic examination and will be assessed
according to EAE/ASE guidelines.
Table 3. Echocardiographic parameters.
Anatomy and function AoV [34–36]
Diameter LVOT, aortic sinus, STJ, ascending aorta
Systolic LV function and dimension [37,38]
Filling pressure and LV diastolic function [39]
RV function [40]
AoV: aortic valve, LVOT: left ventricular outflow tract, STJ: sinotubular junction, LV: left ventricle, RV: right ventricle.
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5.4. Laboratory Assessments
Blood sampling will be conducted by standard venipuncture during all study visits. Standard
hematological parameters (hemoglobin, hematocrit, thrombocytes, leucocytes) and differentiation will
be evaluated. Additional samples will be stored at −80 ◦C for future biomarker analyses investigating
kidney function, vitamin K status and calcification inhibitor concentrations over time. Moreover, the
association between biomarkers and calcification/aortic valve stenosis, left ventricular response and
(long term) diastolic function will be investigated in future analyses.
5.5. Randomization and Study Intervention
Subjects will be randomized after the initial scans in a 1:1 fashion, by an independent investigator,
to the (1) intervention group (MK7) or (2) placebo group (Figure 1). Block randomization (4 or 6
subjects per block) will be assembled to safeguard equal allocation of subjects to the treatment groups.
5.6. Study Intervention
Patients in the intervention group will receive a capsule containing 360 mcg of menaquinone-7
(MK7, NattoPharma ASA, Oslo, Norway) daily for 18 months. Capsules consist of synthetic MK7
(bioequivalent to soy and natural chickpea MenaQ7) [41]. The choice to use MK7 is based on its longer
half-life and its favorable extra-hepatic distribution compared to other forms of vitamin K2 [16]. The
dose to be used in this trial was established in a dose-finding study, in which a positive dose-dependent
effect of menaquinone-7 on MGP- and osteocalcin-carboxylation was found. Non-functional MGP was
decreased most effectively using a daily dose of 360 mcg MK7 [42–44]. Furthermore, MK7 does not
cause a hypercoagulable state and is well-tolerated [45].
The placebo capsule does not differ from the MK7 capsule with regard to shape, taste and
additives, but does not contain MK7.
Patients receive a pre-specified number of tablets at each visit. The next visit, patients will
hand the leftover tablets to the investigator who will provide the patient with the next pre-specified
number of tablets. Compliance will be monitored at each visit by performing and registering a pill
count. Furthermore, vitamin K status and concentration of dephosphorylated uncarboxylated MGP
(dp-ucMGP) over time will be determined at the end of the study.
6. Summary
The BASIK2 study is a proof of concept trial that will provide us with information on calcium
activity in the aortic valve and the potential effect of supplementation with vitamin K2 (more
specifically; MK7). This trial bears the potential to open novel avenues for future large scale randomized
controlled trials to intervene in the progression of CAVS.
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Appendix A
Table A1. Overview of randomized controlled trials performed with various pharmacological interventions with primary endpoints other than calcification in aortic
valve stenosis.
Intervention Trial
Year or
Clinicaltrials.gov
Number
No. of Patients Main Inclusion Criteria Primary Endpoint Conclusion
Simvastatin +
ezetimibe vs.
placebo
SEAS
(Simvastatin and Ezetimibe
Aortic Stenosis) [46]
2008 1873
Patients (45–85 years) with
asymptomatic mild to
moderate aortic valve
stenosis (Vmax 2.5–4.0 m/s)
Major cardiovascular events
No difference in occurrence
of major cardiovascular
events
Rosuvastatin vs.
placebo
ASTRONOMER
(Aortic Stenosis Progression
Observation: Measuring
Effects of Rosuvastatin) [47]
2010 269
Patients (18–82 years) with
asymptomatic mild to
moderate aortic valve
stenosis (Vmax 2.5–4.0 m/s)
Peak gradient and AVA
progression in rosuvastatin
arm vs. placebo (using
echocardiography at baseline
and annual measurements)
Rosuvastatin had no effect
on the progression of aortic
valve stenosis based on
peak gradient and AVA
Rosuvastatin vs.
placebo
PROCAS
(Progression of Stenosis in
Adult Patients With Congenital
Aortic Stenosis) [48]
2011 63
Patients (18–45 years) with
asymptomatic congenital
aortic valve stenosis (Vmax
≥ 2.5 m/s)
Aortic valve stenosis
progression based on Vmax in
rosuvastatin arm vs. placebo
(using echocardiography at
baseline and annual
measurements)
Rosuvastatin had no effect
on the progression of
congenital aortic valve
stenosis (based on Vmax,
mean gradient and AVA)
Fluvastatin vs.
placebo
AORTICA 1
(Randomized Study to
Evaluate the Efficacy of
Fluvastatin on Inflammatory
Markers in Patients With
Aortic Stenosis)
NCT00404287 164
Patients (>18 years) with
asymptomatic aortic valve
stenosis (Vmax > 2 m/s)
Changes in CRP (mg/dL)
concentrations at 12 months Not available
Fluvastatin vs.
placebo
Statin Therapy in
Asymptomatic Aortic Stenosis NCT00176410 100
Patients (21–80 years) with
asymptomatic mild to
moderate aortic valve
stenosis (Vmax > 2.5 m/s,
0.8 <AVA <1.5 cm2)
Progression of aortic valve
stenosis and hemodynamic
parameters (using TTE and
catheterization at 24 months)
Not available
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Table A1. Cont.
Intervention Trial
Year or
Clinicaltrials.gov
Number
No. of Patients Main Inclusion Criteria Primary Endpoint Conclusion
Ramipril vs.
placebo
RIAS
(a prospective, double-blind,
randomized controlled trial of
the angiotensin-converting
enzyme inhibitor ramipril in
aortic stenosis) [49]
2015 100
Patients (>18 years) with
asymptomatic moderate to
severe aortic valve stenosis
(valve area < 1.5 cm2 or
Vmax > 3.0 m/s) without
indications for valve
replacement surgery
Change in LVM in the
ramipril arm vs. the placebo
arm (using CMR at baseline
at 6 months and 1 year)
Modest (but significant)
difference in LVM between
the two groups after 1 year
(regression of LVM in the
ramipril arm vs. increased
LVM in the placebo arm)
Captopril and
trandolapril vs.
placebo
ACCESS
(Acute Haemodynamic Effects
of Treatment With Angiotensin
Converting Enzyme
(ACE)-inhibitors in Patients
With Symptomatic Aortic
Stenosis
NCT00252317 64
Patients (>18 years) with
asymptomatic and
symptomatic severe aortic
valve stenosis (AVA <
1.0 cm2)
Improvement of
haemodynamic parameters
after 8 weeks of treatment
with ACE-inhibitor vs.
placebo
Not available
Eplerenone vs.
placebo
ZEST
(A randomized trial of the
aldosterone-receptor
antagonist, eplerenone, in
asymptomatic
moderate–severe aortic
stenosis) [50]
2008 65
Patients with
asymptomatic moderate to
severe aortic valve stenosis
(Vmax > 3.0 m/s) with
ejection fraction > 50%,
without indications for
valve replacement surgery
Delay of onset of LV systolic
dysfunction or reduction of
progression of LV
hypertrophy in the
eplerenone arm vs. placebo
(using CMR)
Eplerenone did not show a
clear effect on primary
endpoints.
Candesartan vs.
placebo
Is blockade of the
renin–angiotensin system able
to reverse the structural and
functional remodeling of the
left ventricle in severe aortic
stenosis? [51]
2015 51
Patients (>18 years) with
severe aortic valve stenosis
referred for valve
replacement surgery
Changes in LV structure and
function and improvement of
exercise capacity in the
eplerenone arm vs. placebo
(at 5 months)
Candesartan did not have
favorable effects on the left
ventricle or exercise
tolerance.
Candesartan vs.
placebo
ROCK-AS (The Potential of
Candesartan to Retard the
Progression of Aortic Stenosis)
NCT00699452 120
Patients (>18 years) with
clinically symptomatic
severe aortic valve stenosis,
not treated with
ACE-inhibitors or AT1R
antagonists
Inflammation in the valves at
3–5 months Not available
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Table A1. Cont.
Intervention Trial
Year or
Clinicaltrials.gov
Number
No. of Patients Main Inclusion Criteria Primary Endpoint Conclusion
Fimasartan vs.
placebo
ALFA
(A Randomized Trial of
Angiotensin Receptor bLocker,
Fimasarta, in Aortic Stenosis)
NCT01589380 100
Patients (20–75 years), with
moderate to severe
(asymptomatic) aortic
valve stenosis (Vmax
3.0–4.5 m/s, mean gradient
25–49 mmHg or AVA
0.76–1.5 cm2), able to
undergo cardiopulmonary
exercise testing
Change in VO2max during
cardiopulmonary exercise
testing at 1 year
Not available
Tadalafil vs.
placebo
ASPEN
(Aortic stenosis and
phosphodiesterase type 5
inhibition: a pilot study)
NCT01275339 56
Patients (>18 years) with
moderate to severe aortic
valve stenosis (AVA <
1.5 cm2), without
indications for valve
replacement surgery
Change in LVM (using CMR
at 6 months), change in
diastolic function (using
tissue Doppler e’ at 12 weeks
and 6 months) and change in
LV longitudinal peak systolic
strain (using
echocardiography at
12 weeks and 6 months)
Not available.
ACE: angiotensin-converting-enzyme, AT1R: Type 1 angiotensin II receptor, AVA: aortic valve area, CMR: cardiac magnetic resonance, CRP: C-reactive protein, CT: computed tomography,
LVEF: left ventricular ejection fraction, LVM: left ventricular mass, RAS: renin-angiotensin system, TTE: transthoracic echocardiography, Vmax: peak velocity.
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